{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:58:30Z","timestamp":1781877510549,"version":"3.54.5"},"posted":{"date-parts":[[2026,6,19]]},"group-title":"In Review","reference-count":41,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,6,14]]},"abstract":"<title>Abstract<\/title>\n                <p>Oncogenic KRAS mutations drive a substantial proportion of lung cancers and are linked to poor prognosis, positioning KRAS as a compelling target for cellular immunotherapy. Thirty-five percent of lung adenocarcinomas harbor the KRAS G12C, G12V, G12D mutations. Here, we developed HLA-A*03:01- and HLA-A*11:01-restricted T cell receptors (TCR) targeting the most prevalent G12C and G12V KRAS hotspot mutations in lung adenocarcinoma. Predicted high affinity peptides were screened using our TCR discovery and validation pipeline, and functional assessment was performed to determine sensitivity, specificity, and cytotoxic potential of TCR-engineered T cells. We discovered and validated 5 novel TCRs targeting KRAS G12C and G12V 9-mers, each of which demonstrated an ability to recognize and lyse tumor cells endogenously presenting mutant KRAS on HLA-A*03:01 or HLA-A*11:01. Notably, several TCRs demonstrated distinct modes of cross-reactivity, including peptide degeneracy across KRAS G12 variants, HLA degeneracy across HLA-A*03:01 and HLA-A*11:01, or dual degeneracy across both KRAS and HLA, thereby broadening the treatable target populations. TCRs that recognize the KRAS hotspot shared sequence motifs were found in several lung cancer patients. Our study highlights the successful generation of multi-valent KRAS-specific TCRs and supports the feasibility of targeting shared KRAS neoantigens through TCR engineering in lung cancer.<\/p>","DOI":"10.21203\/rs.3.rs-10030408\/v1","type":"posted-content","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:43:17Z","timestamp":1781876597000},"source":"Crossref","is-referenced-by-count":0,"title":["Dual-degenerate TCRs target multiple KRAS hotspot and HLA-A3 family combinations"],"prefix":"10.21203","author":[{"given":"Minying","family":"Zhang","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Nassif","family":"Rausseo","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixin","family":"Jiang","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Bontekoe","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Montoya","family":"Alves","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Slone","sequence":"additional","affiliation":[{"name":"Rice University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waree","family":"Rinsurongkawong","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadeerat","family":"Rinsurongkawong","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"Patel","sequence":"additional","affiliation":[{"name":"Rice University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Lewis","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Davies","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hwu","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Lee","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Wistuba","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ara","family":"Vaporciyan","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Deniger","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Lizee","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassian","family":"Yee","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Kavraki","sequence":"additional","affiliation":[{"name":"Rice University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Gibbons","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Tran","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Zhang","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Heymach","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Reuben","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1038\/s41467-021-22125-z","article-title":"The origins and genetic interactions of KRAS mutations are allele- and tissue-specific","volume":"12","author":"Cook JH","year":"2021","unstructured":"Cook JH, Melloni GEM, Gulhan DC, Park PJ, Haigis KM (2021) The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. Nat Commun 12(1):1808","journal-title":"Nat Commun"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS Proteins and Their Regulators in Human Disease","volume":"170","author":"Dhirendra KS","year":"2017","unstructured":"Dhirendra KS, Dwight VN, Frank M (2017) RAS Proteins and Their Regulators in Human Disease. Cell 170(1):17\u201333","journal-title":"Cell"},{"issue":"9","key":"ref3","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.annonc.2021.06.001","article-title":"Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches","volume":"32","author":"Reck M","year":"2021","unstructured":"Reck M, Carbone DP, Garassino M, Barlesi F (2021) Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol 32(9):1101\u20131110","journal-title":"Ann Oncol"},{"issue":"25","key":"ref4","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired Resistance to KRAS G12C Inhibition in Cancer","volume":"384","author":"Awad MM","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW et al (2021) Acquired Resistance to KRAS G12C Inhibition in Cancer. N Engl J Med 384(25):2382\u20132393","journal-title":"N Engl J Med"},{"issue":"23","key":"ref5","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer","volume":"375","author":"Tran E","year":"2016","unstructured":"Tran E, Robbins PF, Lu Y-C, Prickett TD, Gartner JJ, Jia L et al (2016) T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med 375(23):2255\u20132262","journal-title":"N Engl J Med"},{"issue":"8","key":"ref6","doi-asserted-by":"crossref","first-page":"e22939","DOI":"10.1371\/journal.pone.0022939","article-title":"Natural splice variant of MHC class I cytoplasmic tail enhances dendritic cell-induced CD8\u2009+\u2009T-cell responses and boosts anti-tumor immunity","volume":"6","author":"Rodriguez-Cruz TG","year":"2011","unstructured":"Rodriguez-Cruz TG, Liu S, Khalili JS, Whittington M, Zhang M, Overwijk W et al (2011) Natural splice variant of MHC class I cytoplasmic tail enhances dendritic cell-induced CD8\u2009+\u2009T-cell responses and boosts anti-tumor immunity. PLoS ONE 6(8):e22939","journal-title":"PLoS ONE"},{"issue":"W1","key":"ref7","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson B","year":"2020","unstructured":"Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M (2020) NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res 48(W1):W449\u2013W54","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s43018-021-00210-y","article-title":"Targeting public neoantigens for cancer immunotherapy","volume":"2","author":"Pearlman AH","year":"2021","unstructured":"Pearlman AH, Hwang MS, Konig MF, Hsiue EH, Douglass J, DiNapoli SR et al (2021) Targeting public neoantigens for cancer immunotherapy. Nat Cancer 2(5):487\u2013497","journal-title":"Nat Cancer"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"e003082","DOI":"10.1136\/jitc-2021-003082","article-title":"Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes","volume":"10","author":"Shah P","year":"2022","unstructured":"Shah P, Forget M-A, Frank ML, Jiang P, Sakellariou-Thompson D, Federico L et al (2022) Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. J Immunother Cancer 10(2):e003082","journal-title":"J Immunother Cancer"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"e89357","DOI":"10.1371\/journal.pone.0089357","article-title":"Measuring Cytotoxicity by Bioluminescence Imaging Outperforms the Standard Chromium-51 Release Assay","volume":"9","author":"Karimi MA","year":"2014","unstructured":"Karimi MA, Lee E, Bachmann MH, Salicioni AM, Behrens EM, Kambayashi T et al (2014) Measuring Cytotoxicity by Bioluminescence Imaging Outperforms the Standard Chromium-51 Release Assay. PLoS ONE 9(2):e89357","journal-title":"PLoS ONE"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1089\/hum.2005.16.457","article-title":"Transfer of a TCR Gene Derived from a Patient with a Marked Antitumor Response Conveys Highly Active T-Cell Effector Functions","volume":"16","author":"Hughes MS","year":"2005","unstructured":"Hughes MS, Yu YYL, Dudley ME, Zheng Z, Robbins PF, Li Y et al (2005) Transfer of a TCR Gene Derived from a Patient with a Marked Antitumor Response Conveys Highly Active T-Cell Effector Functions. Hum Gene Ther 16(4):457\u2013472","journal-title":"Hum Gene Ther"},{"key":"ref12","author":"Rasko JEJ","year":"1999","unstructured":"Rasko JEJ, Battini J-L, Gottschalk RJ, Mazo I, Miller AD (1999) The RD114\/simian type D retrovirus receptor is a neutral amino acid transporter. Proceedings of the National Academy of Sciences. ;96(5):2129\u201334"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41587-020-0505-4","article-title":"Analyzing the Mycobacterium tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-wide antigen screening","volume":"38","author":"Huang H","year":"2020","unstructured":"Huang H, Wang C, Rubelt F, Scriba TJ, Davis MM (2020) Analyzing the Mycobacterium tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-wide antigen screening. Nat Biotechnol 38(10):1194\u20131202","journal-title":"Nat Biotechnol"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1021\/acs.jcim.3c01667","article-title":"APE-Gen2.0: Expanding Rapid Class I Peptide\u2013Major Histocompatibility Complex Modeling to Post-Translational Modifications and Noncanonical Peptide Geometries","volume":"64","author":"Fasoulis R","year":"2024","unstructured":"Fasoulis R, Rigo MM, Liz\u00e9e G, Antunes DA, Kavraki LE (2024) APE-Gen2.0: Expanding Rapid Class I Peptide\u2013Major Histocompatibility Complex Modeling to Post-Translational Modifications and Noncanonical Peptide Geometries. J Chem Inf Model 64(5):1730\u20131750","journal-title":"J Chem Inf Model"},{"issue":"7","key":"ref15","doi-asserted-by":"crossref","first-page":"e1005659","DOI":"10.1371\/journal.pcbi.1005659","article-title":"OpenMM 7: Rapid development of high performance algorithms for molecular dynamics","volume":"13","author":"Eastman P","year":"2017","unstructured":"Eastman P, Swails J, Chodera JD, McGibbon RT, Zhao Y, Beauchamp KA et al (2017) OpenMM 7: Rapid development of high performance algorithms for molecular dynamics. PLoS Comput Biol 13(7):e1005659","journal-title":"PLoS Comput Biol"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"e0155183","DOI":"10.1371\/journal.pone.0155183","article-title":"Vinardo: A Scoring Function Based on Autodock Vina Improves Scoring, Docking, and Virtual Screening","volume":"11","author":"Quiroga R","year":"2016","unstructured":"Quiroga R, Villarreal MA (2016) Vinardo: A Scoring Function Based on Autodock Vina Improves Scoring, Docking, and Virtual Screening. PLoS ONE 11(5):e0155183","journal-title":"PLoS ONE"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pro.3943","article-title":"UCSF ChimeraX: Structure visualization for researchers, educators, and developers","volume":"30","author":"Pettersen EF","year":"2021","unstructured":"Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI et al (2021) UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci 30(1):70\u201382","journal-title":"Protein Sci"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.968064","article-title":"KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population","volume":"12","author":"Fancelli S","year":"2022","unstructured":"Fancelli S, Caliman E, Mazzoni F, Paglialunga L, Gatta Michelet MR, Lavacchi D et al (2022) KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population. Front Oncol. ;12","journal-title":"Front Oncol"},{"issue":"19","key":"ref19","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.3390\/cancers14194933","article-title":"Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors","volume":"14","author":"Zhao D","year":"2022","unstructured":"Zhao D, Li H, Mambetsariev I, Mirzapoiazova T, Chen C, Fricke J et al (2022) Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Cancers 14(19):4933","journal-title":"Cancers"},{"issue":"16suppl","key":"ref20","doi-asserted-by":"crossref","first-page":"9069","DOI":"10.1200\/JCO.2023.41.16_suppl.9069","article-title":"Spectrum of acquired KRAS mutations in driver mutation-positive non-small cell lung cancer","volume":"41","author":"Reuss JE","year":"2023","unstructured":"Reuss JE, Gandhi N, Walker P, Nieva JJ, Alvarez JGB, Carlisle JW et al (2023) Spectrum of acquired KRAS mutations in driver mutation-positive non-small cell lung cancer. J Clin Oncol 41(16suppl):9069","journal-title":"J Clin Oncol"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"100084","DOI":"10.1016\/j.crmeth.2021.100084","article-title":"Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations","volume":"1","author":"Choi J","year":"2021","unstructured":"Choi J, Goulding SP, Conn BP, McGann CD, Dietze JL, Kohler J et al (2021) Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations. Cell Rep Methods 1(5):100084","journal-title":"Cell Rep Methods"},{"issue":"6","key":"ref22","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2326-6066.CIR-25-0605","article-title":"FOXM1-Specific TCR-Engineered T Cells Target Non-Small Cell Lung Cancer","volume":"14","author":"Bontekoe E","year":"2026","unstructured":"Bontekoe E, Zhang M, Jiang P, Montoya A, Shulga Y, Slone JK et al (2026) FOXM1-Specific TCR-Engineered T Cells Target Non-Small Cell Lung Cancer. Cancer Immunol Res 14(6):958\u2013973","journal-title":"Cancer Immunol Res"},{"key":"ref23","author":"Guillaume P","year":"2018","unstructured":"Guillaume P, Picaud S, Baumgaertner P, Montandon N, Schmidt J, Speiser DE et al (2018) The C-terminal extension landscape of naturally presented HLA-I ligands. Proceedings of the National Academy of Sciences. ;115(20):5083\u20138"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41587-019-0322-9","article-title":"A large peptidome dataset improves HLA class I epitope prediction across most of the human population","volume":"38","author":"Sarkizova S","year":"2020","unstructured":"Sarkizova S, Klaeger S, Le PM, Li LW, Oliveira G, Keshishian H et al (2020) A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat Biotechnol 38(2):199\u2013209","journal-title":"Nat Biotechnol"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41587-019-0322-9","article-title":"A large peptidome dataset improves HLA class I epitope prediction across most of the human population","volume":"38","author":"Sarkizova S","year":"2020","unstructured":"Sarkizova S, Klaeger S, Le PM, Li LW, Oliveira G, Keshishian H et al (2020) A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat Biotechnol 38(2):199\u2013209","journal-title":"Nat Biotechnol"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41467-019-14273-0","article-title":"Comprehensive T cell repertoire characterization of non-small cell lung cancer","volume":"11","author":"Reuben A","year":"2020","unstructured":"Reuben A, Zhang J, Chiou S-H, Gittelman RM, Li J, Lee W-C et al (2020) Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun 11(1):603","journal-title":"Nat Commun"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1038\/s41467-023-42010-1","article-title":"KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors","volume":"14","author":"Lu D","year":"2023","unstructured":"Lu D, Chen Y, Jiang M, Wang J, Li Y, Ma K et al (2023) KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors. Nat Commun 14(1):6389","journal-title":"Nat Commun"},{"issue":"D1","key":"ref28","doi-asserted-by":"crossref","first-page":"D604","DOI":"10.1093\/nar\/gkae840","article-title":"TCR3d 2.0: expanding the T cell receptor structure database with new structures, tools and interactions","volume":"53","author":"Lin V","year":"2025","unstructured":"Lin V, Cheung M, Gowthaman R, Eisenberg M, Baker BM, Pierce BG (2025) TCR3d 2.0: expanding the T cell receptor structure database with new structures, tools and interactions. Nucleic Acids Res 53(D1):D604\u2013D8","journal-title":"Nucleic Acids Res"},{"issue":"21","key":"ref29","article-title":"Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors","volume":"134","author":"Bear AS","year":"2024","unstructured":"Bear AS, Nadler RB, O\u2019Hara MH, Stanton KL, Xu C, Saporito RJ et al (2024) Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors. J Clin Investig. ;134(21)","journal-title":"J Clin Investig"},{"issue":"9","key":"ref30","doi-asserted-by":"crossref","first-page":"2451079","DOI":"10.1002\/eji.202451079","article-title":"Identification and structural characterization of a mutant KRAS-G12V specific TCR restricted by HLA-A3","volume":"54","author":"Sim MJW","year":"2024","unstructured":"Sim MJW, Hanada K-i, Stotz Z, Yu Z, Lu J, Brennan P et al (2024) Identification and structural characterization of a mutant KRAS-G12V specific TCR restricted by HLA-A3. Eur J Immunol 54(9):2451079","journal-title":"Eur J Immunol"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1158\/2326-6066.CIR-15-0188","article-title":"Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors","volume":"4","author":"Wang QJ","year":"2016","unstructured":"Wang QJ, Yu Z, Griffith K, Hanada K-i, Restifo NP, Yang JC (2016) Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. Cancer Immunol Res 4(3):204\u2013214","journal-title":"Cancer Immunol Res"},{"issue":"22","key":"ref32","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer","volume":"386","author":"Leidner R","year":"2022","unstructured":"Leidner R, Silva NS, Huang H, Sprott D, Zheng C, Shih Y-P et al (2022) Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. N Engl J Med 386(22):2112\u20132119","journal-title":"N Engl J Med"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1038\/s41467-022-32811-1","article-title":"Therapeutic high affinity T cell receptor targeting a KRAS(G12D) cancer neoantigen","volume":"13","author":"Poole A","year":"2022","unstructured":"Poole A, Karuppiah V, Hartt A, Haidar JN, Moureau S, Dobrzycki T et al (2022) Therapeutic high affinity T cell receptor targeting a KRAS(G12D) cancer neoantigen. Nat Commun 13(1):5333","journal-title":"Nat Commun"},{"issue":"16suppl","key":"ref34","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1200\/JCO.2023.41.16_suppl.2547","article-title":"Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared\u2009<\u2009i>KRAS\u2009and TP53 mutations expressed by solid tumors in first-in-human phase 1 study","volume":"41","author":"Morelli MP","year":"2023","unstructured":"Morelli MP, Negrao MV, Collinson-Pautz MR, Jernigan K, Demars NA, Weitzman A et al (2023) Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared\u2009<\u2009i>KRAS\u2009and TP53 mutations expressed by solid tumors in first-in-human phase 1 study. J Clin Oncol 41(16suppl):2547","journal-title":"J Clin Oncol"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"26851","DOI":"10.1038\/s41598-024-75140-7","article-title":"Broadening alloselectivity of T cell receptors by structure guided engineering","volume":"14","author":"Karuppiah V","year":"2024","unstructured":"Karuppiah V, Sangani D, Whaley L, Pengelly R, Uluocak P, Carreira RJ et al (2024) Broadening alloselectivity of T cell receptors by structure guided engineering. Sci Rep 14(1):26851","journal-title":"Sci Rep"},{"issue":"1\u20132","key":"ref36","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.molimm.2011.08.015","article-title":"Structural basis of cross-allele presentation by HLA-A*0301 and HLA-A*1101 revealed by two HIV-derived peptide complexes","volume":"49","author":"Zhang S","year":"2011","unstructured":"Zhang S, Liu J, Cheng H, Tan S, Qi J, Yan J et al (2011) Structural basis of cross-allele presentation by HLA-A*0301 and HLA-A*1101 revealed by two HIV-derived peptide complexes. Mol Immunol 49(1\u20132):395\u2013401","journal-title":"Mol Immunol"},{"issue":"7","key":"ref37","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/intimm\/dxl052","article-title":"T cell receptor cross-recognition of an HIV-1 CD8\u2009+\u2009T cell epitope presented by closely related alleles from the HLA-A3 superfamily","volume":"18","author":"Lichterfeld M","year":"2006","unstructured":"Lichterfeld M, Williams KL, Mui SK, Shah SS, Mothe BR, Sette A et al (2006) T cell receptor cross-recognition of an HIV-1 CD8\u2009+\u2009T cell epitope presented by closely related alleles from the HLA-A3 superfamily. Int Immunol 18(7):1179\u20131188","journal-title":"Int Immunol"},{"key":"ref38","unstructured":"SEER [Available from https:\/\/seer.cancer.gov\/statfacts\/html\/common.html"},{"key":"ref39","author":"Siegel RL","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A, Cancer statistics (2024) CA: A Cancer Journal for Clinicians. 2024;74(1):12\u201349"},{"key":"ref40","unstructured":"CDC [Available from https:\/\/www.cdc.gov\/united-states-cancer-statistics\/publications\/lung-cancer-types.html"},{"key":"ref41","unstructured":"NCI Genomic Data Commons [Available from: https:\/\/portal.gdc.cancer.gov\/"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10030408\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10030408\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:44:15Z","timestamp":1781876655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10030408\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":41,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-10030408\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,6,19]]},"subtype":"preprint"}}